The November 2 webcast and any subsequent Phase 3 initiation announcement are the next catalysts. Monitor for potential partnership interest given the broad CLDN18.2 expression activity and FDA alignment, which could de-risk the program for a larger pharma partner.
Price Chart
Executive Summary
NovaBridge presented updated Phase 1b data for givastomig at ESMO 2026, showing an 79% objective response rate and 16.9-month median progression-free survival at the selected 8 mg/kg dose in first-line metastatic gastroesophageal adenocarcinoma. The company has aligned with the FDA on a Phase 3 study design and holds Orphan Drug and Fast Track Designations, positioning givastomig as a registrational-ready program. For a $153M market cap biotech with a single lead asset, this data maturation and regulatory progress represent a significant value inflection point.
Key Facts
- Updated Phase 1b data for givastomig (CLDN18.2 x 4-1BB bispecific) in first-line HER2-negative metastatic gastroesophageal adenocarcinoma presented at ESMO 2026
- At selected 8 mg/kg dose: 79% objective response rate (23/29), 97% disease control rate, median duration of response 15.2 months, median progression-free survival 16.9 months, median follow-up 17.8 months
- Clinical activity observed across CLDN18.2 expression levels: 82% ORR in ≥75% expression, 75% ORR in 1%-74% expression
- No Grade 4 or Grade 5 treatment-related adverse events attributed to givastomig; safety profile manageable
- FDA alignment achieved on global registrational study protocol, Phase 3 study design, intended patient population, dose, and primary endpoints
- Orphan Drug Designation and Fast Track Designation granted by FDA
- Investor webcast scheduled for November 2, 2026 to discuss data and registrational strategy
Financial Impact
NovaBridge has a $153M market cap with givastomig as its lead asset; positive Phase 1b data and FDA alignment for Phase 3 could significantly increase valuation if registrational success is achieved, but no revenue or deal value is stated in the release.
Risk Factors
- Phase 3 trial may fail to replicate Phase 1b efficacy or safety results
- Competition from approved CLDN18.2-targeted therapies (e.g., zolbetuximab) and other bispecifics in development
- NovaBridge's ability to fund a global Phase 3 trial without dilutive financing or a partnership is uncertain given its $153M market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387722 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.49 | awaiting T+5 | — | $1.22 (−18.46%) |
Oct 25, 2026 1d ago | Press Release | $1.42 | awaiting T+5 | — | $1.22 (−14.44%) |
Oct 23, 2026 3d ago | 6-K | $1.37 | awaiting T+5 | — | $1.22 (−11.31%) |
Oct 13, 2026 13d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.22 (−5.81%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.22 (−36.39%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.22 (−31.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers